000154378 001__ 154378
000154378 005__ 20240411115843.0
000154378 0247_ $$2doi$$a10.3390/jcm9092683
000154378 0247_ $$2pmid$$apmid:32824982
000154378 0247_ $$2pmc$$apmc:PMC7563270
000154378 0247_ $$2altmetric$$aaltmetric:88799746
000154378 037__ $$aDZNE-2021-00231
000154378 041__ $$aEnglish
000154378 082__ $$a610
000154378 1001_ $$0P:(DE-2719)9001490$$aRoessling, Rosa$$b0$$eFirst author$$udzne
000154378 245__ $$aApheresis in Autoimmune Encephalitis and Autoimmune Dementia.
000154378 260__ $$aBasel$$bMDPI$$c2020
000154378 3367_ $$2DRIVER$$aarticle
000154378 3367_ $$2DataCite$$aOutput Types/Journal article
000154378 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712750863_11350$$xReview Article
000154378 3367_ $$2BibTeX$$aARTICLE
000154378 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154378 3367_ $$00$$2EndNote$$aJournal Article
000154378 500__ $$aISSN 2077-0383 not unique: **3 hits**.
000154378 520__ $$aAutoimmune encephalitis (AE) is a rapidly progressive inflammatory neurological disease. Underlying autoantibodies can bind to neuronal surfaces and synaptic proteins resulting in psychiatric symptoms, focal neurological signs, autonomic dysfunction and cognitive decline. Early and effective treatment is mandatory to reduce clinical symptoms and to achieve remission. Therapeutic apheresis, involving both plasma exchange (PE) and immunoadsorption (IA), can rapidly remove pathogenic antibodies from the circulation, thus representing an important first-line treatment in AE patients. We here review the most relevant studies regarding therapeutic apheresis in AE, summarizing the outcome for patients and the expanding clinical spectrum of treatment-responsive clinical conditions. For example, patients with slowly progressing cognitive impairment suggesting a neurodegenerative dementia can have underlying autoantibodies and improve with therapeutic apheresis. Findings are encouraging and have led to the first ongoing clinical studies assessing the therapeutic effect of IA in patients with anti-neuronal autoantibodies and the clinical presentation of dementia. Therapeutic apheresis is an established and well tolerated option for first-line therapy in AE and, potentially, other antibody-mediated central nervous system diseases.
000154378 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000154378 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000154378 650_7 $$2Other$$aNMDAR (N-Methyl-D-Aspartat)
000154378 650_7 $$2Other$$aantibody
000154378 650_7 $$2Other$$aapheresis
000154378 650_7 $$2Other$$aautoimmune encephalitis
000154378 650_7 $$2Other$$aimmunoadsorption
000154378 650_7 $$2Other$$alimbic encephalitis
000154378 650_7 $$2Other$$aparaneoplastic
000154378 650_7 $$2Other$$aplasma exchange
000154378 7001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b1$$eLast author
000154378 770__ $$aApheresis in Neurological Disorders
000154378 773__ $$0PERI:(DE-600)2662592-1$$a10.3390/jcm9092683$$gVol. 9, no. 9, p. 2683 -$$n9$$p2683$$tJournal of Clinical Medicine$$v9$$x2077-0383$$y2020
000154378 8564_ $$uhttps://pub.dzne.de/record/154378/files/DZNE-2021-00231.pdf$$yOpenAccess
000154378 8564_ $$uhttps://pub.dzne.de/record/154378/files/DZNE-2021-00231.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154378 909CO $$ooai:pub.dzne.de:154378$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000154378 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001490$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000154378 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000154378 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000154378 9132_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154378 9141_ $$y2020
000154378 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000154378 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-05
000154378 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN MED : 2021$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-04T08:13:34Z
000154378 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-05
000154378 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-04T08:13:34Z
000154378 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154378 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-05
000154378 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-05
000154378 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000154378 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-05
000154378 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000154378 980__ $$ajournal
000154378 980__ $$aVDB
000154378 980__ $$aUNRESTRICTED
000154378 980__ $$aI:(DE-2719)1810003
000154378 9801_ $$aFullTexts